-
Sections on this page

Publications

Selected publications from Prof David Ashley

Owens E, Hotchkiss K, Brown M, Threatt S, Low J, Anand M, Goldston M, Johnson M, Bradbury C, Herndon J, Grant G, Ashley D, Patel A, Desjardins A, Khasraw M. Oncolytic HSV-1 Encoding IL-12 and Anti-PD-1 Reprograms CNS Immunity: Open-Label Study of MVR-C5252 for Safety, Tolerability, and Efficacy (PuMP) 2259418. The Journal of Immunology. 2026;215(Supplement_1):10.1093/jimmun/vkag141.710

Louw J, Zhang K, Corcoran A, Owens E, Jepson J, Conejo-Garcia J, Ashley D, Mirchia K, Raleigh D, Khasraw M. Spatial Transcriptomics Reveals Immune Remodeling in Recurrent Oligodendroglioma 2259684. The Journal of Immunology. 2026;215(Supplement_1):10.1093/jimmun/vkag141.763

Hotchkiss K, Norberg P, Buckley E, Owens E, Ayasoufi K, Threatt S, Low J, Shoaf M, Goldston M, Batich K, Johnson M, Herndon J, Nair S, Weinhold K, Friedman H, Ashley D, Desjardins A, Sampson J, Khasraw M. A universal CD4 epitope enhances cytotoxic T-cell priming and memory in glioblastoma peptide vaccination 2257077. The Journal of Immunology. 2026;215(Supplement_1):10.1093/jimmun/vkag141.388

Young E, Govender D, Waldeck K, Gottardo N, Strong R, Kinross K, Carr M, Jones J, Wong L, Ziegler D, Hansford J, Michael M, Tremblay C, Rudkin A, Winstanley M, Desai J, Ashley D, Cain J, Wood P. ID #672 A phase II study of continuous low dose panobinostat in paediatric patients with atypical teratoid rhabdoid tumours (ATRT).Neuro-Oncology Pediatrics. 2026;2(Supplement_1):10.1093/neuped/wuag026.271

Minor M, Zhang J, Elkholi R, Dewey J, Patel M, Savelli A, Johnson M, Batich K, Low J, Shoaf M, Khasraw M, DesJardins A, Friedman H, Ashley D, Calabrese E, Peters K. Response to Next Intervention After Off-label Ivosidenib Treatment Failure in Patients With Mutant IDH Low Grade Glioma (S28.003). Neurology. 2026;106(11_Supplement_1):10.1212/wnl.0000000000216670

Teraishi A, Sanvito F, Raymond C, Cho NS, Norris J, Gandhi S, Cohen AR, Hafizka Y, Luo A, Sim H-W, Wachsmuth LP, Yip S, Koh E-S, Hall M, Ashley DM, Rosenthal MA, Hovey EJ, Gan HK, Johnson MO, Barnes EH, Simes JR, Lwin Z, Khasraw M, Salamon N, Cloughesy TF, Ellingson BM. Automated imaging response evaluation system: Prototype software tool for standardized radiographic response assessment in glioblastoma clinical trials. Neuro-Oncology Practice. 2026;:10.1093/nop/npag039

Wei S, Deng Y, Lee J, Lan H, Yang Z, Labrie M, Betts CB, Duan H, Tate B, Pucilowska J, Frederick D, Lawless AR, Sharova T, Yang Y, Hu W, Beasley GM, Schuchter LM, Wang X, Xu W, Yong G, Vandenberg MEG, Torigian DA, Sivagnanam S, Du K, Sugarman E, McGettigan S, Zheng C, Al-Rohil RN, Selim MA, Datto MB, López GY, Nair SK, Ashley DM, Xu X, Amaravadi RK, Karakousis GC, O’Rourke DM, Brem S, O’Malley BW, Demirkan G, Yu S, Lu Y, Camp T, Patterson JA, Wei Z, Corless C, Gabrilovich DI, Mou Y, Flaherty KT, Coussens LM, Boland G, Herlyn M, Mills G, Liu L, Zhang G. A longitudinal, multi-omic atlas reveals the emergence of a spatially organized immunosuppressive ecosystem in resistant melanoma. Cell Reports Medicine. 2026;7(4):10.1016/j.xcrm.2026.102716

Barnwal A, Yan W, Cook SL, Urup T, Stevenson K, He Y, Osorio C, Parker S, Edouard E, Bowie M, Jackson HC, McLendon RE, Desjardins A, Ashley DM, Bigner DD, Chandramohan V. Anti-VEGF vascular remodeling drives germinal center B cell-rich tertiary lymphoid structures during antibody-toxin and anti-CD40 combination therapy in glioblastoma. 2026;:10.21203/rs.3.rs-9350019/v1

Owens E, Hotchkiss K, Threatt S, Low JT, Anand M, Louw J, Goldston M, Johnson MO, Bradbury C, Herndon JE, Grant GA, Ashley DM, Patel AP, Desjardins A, Brown MC, Khasraw M. Abstract 7769: IL-12/anti-PD-1 armored oncolytic HSV-1 reprograms CNS immunity: Integrated longitudinal immune, genomic, and metabolic CSF profiling in the MVR-C5252 PuMP Trial. Cancer Research. 2026;86(7_Supplement):10.1158/1538-7445.am2026-7769

Benz MC, Zhang K, Ashley DM, Garde C, Singh K, Rasmus OA, Rønø B, Kleine-Kohlbrecher D, Thorsen SF, Hotchkiss KM, Conejo-Garcia JR, Khasraw M. Abstract 6975: Endogenous retrovirus-derived neoantigens enable a personalized cancer vaccine strategy for glioblastoma. Cancer Research. 2026;86(7_Supplement):10.1158/1538-7445.am2026-6975

Interested in supporting our research?

Your support will help WEHI’s researchers make discoveries and find treatments to ensure healthier, longer lives for you and your loved ones.

Contact our friendly team to find out how you can help.

"*" indicates required fields